Abstract
MONARCH 2 (M2) demonstrated that the addition of continuously-dosed abemaciclib to fulvestrant significantly improved progression-free survival (PFS) and overall survival (OS) compared to placebo plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who had progressed on endocrine therapy (ET). Here we present the Objective Response Rate (ORR) from endocrine-naïve (EN) participants enrolled in MONARCH 2.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
